UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 128

Sortiert nach

O-GlcNAcylation in Chronic Lymphocytic Leukemia and Other Blood Cancers

Frontiers in immunology, 2021-11, Vol.12, p.772304-772304

Spaner, David E

2021

Volltextzugriff (PDF)

Characterization of CD200 Ectodomain Shedding

PloS one, 2016-04, Vol.11 (4), p.e0152073-e0152073

2016

Volltextzugriff (PDF)

Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells

The Journal of immunology (1950), 2020-11, Vol.205 (10), p.2629-2639

2020

Volltextzugriff (PDF)

Cytokine Modulation of TLR Expression and Activation in Mesenchymal Stromal Cells Leads to a Proinflammatory Phenotype

The Journal of immunology (1950), 2009-06, Vol.182 (12), p.7963-7973

2009

Volltextzugriff (PDF)

A link between hypercholesterolemia and chronic lymphocytic leukemia

Leukemia & lymphoma, 2016-04, Vol.57 (4), p.797-802

2016

Volltextzugriff (PDF)

High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells

Blood, 2016-08, Vol.128 (7), p.934-947

2016

Volltextzugriff (PDF)

Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia

Blood, 2011-03, Vol.117 (9), p.2668-2680

2011

Volltextzugriff (PDF)

Targeting the IL-17/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo/in vitro

Leukemia research, 2018-03, Vol.66, p.28-38

2018

Volltextzugriff (PDF)

Paradoxical activation of chronic lymphocytic leukemia cells by ruxolitinib in vitro and in vivo

Frontiers in oncology, 2023-04, Vol.13, p.1043694-1043694

2023

Volltextzugriff (PDF)

Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial

Haematologica (Roma), 2016-05, Vol.101 (5), p.e192

2016

Volltextzugriff (PDF)

PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia

Blood, 2013-08, Vol.122 (6), p.969-980

2013

Volltextzugriff (PDF)

Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A

Blood, 2015-08, Vol.126 (6), p.766-778

2015

Volltextzugriff (PDF)

Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells

Leukemia, 2019-07, Vol.33 (7), p.1650-1662

2019

Volltextzugriff (PDF)

Soluble CD200 Is Critical to Engraft Chronic Lymphocytic Leukemia Cells in Immunocompromised Mice

Cancer research (Chicago, Ill.), 2012-10, Vol.72 (19), p.4931-4943

2012

Volltextzugriff (PDF)

Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial

Cancer medicine (Malden, MA), 2021-12, Vol.10 (24), p.8789-8798

2021

Volltextzugriff (PDF)

Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study

Journal of clinical oncology, 2006-12, Vol.24 (34), p.5343-5349

2006

Volltextzugriff (PDF)

Comprehensive Lipidomics Analysis of Bioactive Lipids in Complex Regulatory Networks

Analytical chemistry (Washington), 2010-10, Vol.82 (19), p.8176-8185

2010

Volltextzugriff (PDF)

Persistent janus kinase‐signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial

Cancer medicine (Malden, MA), 2019-04, Vol.8 (4), p.1540-1550

2019

Volltextzugriff (PDF)

The role of CD200 in immunity to B cell lymphoma

Journal of leukocyte biology, 2010-08, Vol.88 (2), p.361-372

2010

Volltextzugriff (PDF)

Low Density Lipoproteins Amplify Cytokine-signaling in Chronic Lymphocytic Leukemia Cells

EBioMedicine, 2017-02, Vol.15 (C), p.24-35

2017

Volltextzugriff (PDF)

Identification of diterpenoid compounds that interfere with Fli-1 DNA binding to suppress leukemogenesis

Cell death & disease, 2019-02, Vol.10 (2), p.117-117, Article 117

2019

Volltextzugriff (PDF)

Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Journal of clinical oncology, 2011-03, Vol.29 (9), p.1175-1181

2011

Volltextzugriff (PDF)

Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells

Oncotarget, 2016-11, Vol.7 (45), p.72608-72621

2016

Volltextzugriff (PDF)

1 – 25 von 128

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(118)
Mit Volltextzugriff
(118)

Publikationsform

Sprache

Englisch
(128)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(73)
Life Sciences & Biomedicine
(71)
Humans
(59)
Male
(30)
Hematology
(29)
Biological And Medical Sciences
(28)
Animals
(27)
Oncology
(27)
Middle Aged
(25)
Female
(24)
Medical Sciences
(23)
Mice
(23)
Aged
(21)
Chronic Lymphocytic Leukemia
(20)
Adult
(18)
Immunology
(17)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(16)
Leukemia, Lymphocytic, Chronic, B-Cell - Immunology
(13)
Hematologic And Hematopoietic Diseases
(12)
Leukemia, Lymphocytic, Chronic, B-Cell - Metabolism
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

O-GlcNAcylation in Chronic Lymphocytic Leukemia and Other Blood Cancers

Characterization of CD200 Ectodomain Shedding

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells

Cytokine Modulation of TLR Expression and Activation in Mesenchymal Stromal Cells Leads to a Proinflammatory Phenotype

A link between hypercholesterolemia and chronic lymphocytic leukemia

High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells

Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia

Targeting the IL-17/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo/in vitro

Paradoxical activation of chronic lymphocytic leukemia cells by ruxolitinib in vitro and in vivo

Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial

PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia

Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A

Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells

Soluble CD200 Is Critical to Engraft Chronic Lymphocytic Leukemia Cells in Immunocompromised Mice

Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial

Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study

Comprehensive Lipidomics Analysis of Bioactive Lipids in Complex Regulatory Networks

Persistent janus kinase‐signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial

The role of CD200 in immunity to B cell lymphoma

Low Density Lipoproteins Amplify Cytokine-signaling in Chronic Lymphocytic Leukemia Cells

Identification of diterpenoid compounds that interfere with Fli-1 DNA binding to suppress leukemogenesis

Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells

Suchergebnisse filtern